WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 26, 2017--
OvaScienceSM (NASDAQ: OVAS), a fertility company focused on
the discovery, development and commercialization of new treatment
options, announced today that it will host a conference call at 4:30
p.m. ET on Thursday, November 2, 2017 to discuss third quarter 2017
financial results and provide a general corporate update.
The conference call may be accessed by dialing +1-888-424-8151 for U.S.
callers and +1-847-585-4422 for international callers five minutes prior
to the start of the call and providing the passcode 9200599. A live
webcast of the conference call will be available online from the
Investors section of the Company’s website at www.ovascience.com.
A replay of the conference call will be available from 7:00 p.m. ET on
Thursday, November 2, 2017, through 11:59 p.m. ET on Thursday, November
16, 2017, and may be accessed by visiting OvaScience’s website or by
dialing 1-888-843-7419 for U.S. callers and 1-630-652-3042 for
international callers. The replay access code is 9200599#.
OvaScienceSM, Inc. (NASDAQ:OVAS)
is a fertility company dedicated to improving treatment options for
women around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because it believes women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining.
OvaScience is developing OvaPrimeSM, which could increase a
woman’s egg reserve and OvaTureSM, a potential in vitro
fertilization (IVF) treatment that could help a woman produce healthy,
fertilizable eggs without hormone injections. OvaScience’s AUGMENTSM
treatment, a fertility option designed to improve IVF success rates, is
available in certain IVF clinics in Canada. OvaScience treatments are
not available in the United States. For more information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026006173/en/
Media and Investor Contact: